ALS skeletal muscle shows enhanced TGF-β signaling, fibrosis and induction of fibro-adipogenic progenitor markersReport as inadecuate

ALS skeletal muscle shows enhanced TGF-β signaling, fibrosis and induction of fibro-adipogenic progenitor markers - Download this document for free, or read online. Document in PDF available to download.

Amyotrophic lateral sclerosis ALS is a fatal neurodegenerative disease in which upper and lower motoneurons degenerate leading to muscle wasting, paralysis and eventually death from respiratory failure. Several studies indicate that skeletal muscle contributes to disease progression; however the molecular mechanisms remain elusive. Fibrosis is a common feature in skeletal muscle under chronic damage conditions such as those caused by muscular dystrophies or denervation. However, the exact mechanisms of fibrosis induction and the cellular bases of this pathological response are unknown. We show that extracellular matrix ECM components are augmented in skeletal muscles of symptomatic hSOD1G93A mice, a widely used murine model of ALS. These mice also show increased TGF-β1 mRNA levels, total Smad3 protein levels and p-Smad3 positive nuclei. Furthermore, platelet-derived growth factor receptor-α PDGFRα, Tcf4 and α-smooth muscle actin α-SMA levels are augmented in the skeletal muscle of symptomatic hSOD1G93A mice. Additionally, the fibro-adipogenic progenitors FAPs, which are the main producers of ECM constituents, are also increased in these pathogenic conditions. Therefore, FAPs and ECM components are more abundant in symptomatic stages of the disease than in pre-symptomatic stages. We present evidence that fibrosis observed in skeletal muscle of symptomatic hSOD1G93A mice is accompanied with an induction of TGF-β signaling, and also that FAPs might be involved in triggering a fibrotic response. Co-localization of p-Smad3 positive cells together with PDGFRα was observed in the interstitial cells of skeletal muscles from symptomatic hSOD1G93A mice. Finally, the targeting of pro-fibrotic factors such as TGF-β, CTGF-CCN2 and platelet-derived growth factor PDGF signaling pathway might be a suitable therapeutic approach to improve muscle function in several degenerative diseases.

Author: David Gonzalez, Osvaldo Contreras, Daniela L. Rebolledo, Juan Pablo Espinoza, Brigitte van Zundert, Enrique Brandan



Related documents